CTRI/2017/10/010253
Completed
未知
Assessment of therapeutic efficacy & safety of Sitopaladi Churna in the Management of Kasa (Stable chronic Bronchitis) - Kasa
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Patients suffering from Chronic Stable Bronchitis and Patients having FEV1 80%.
- Sponsor
- Central Council For Research in Ayurvedic Sciences
- Enrollment
- 67
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients of either sex aged between 18 to 65years.
- •2\.Patients suffering from Chronic Stable Bronchitis. (Chronic Bronchitis is defined as a cough that occurs every day with sputum production that lasts for at least three months, two years in a row).
- •3\.Patients having FEV1 \> 80%.
- •4\.Patient willing and able to participate in the study for 16 weeks.
Exclusion Criteria
- •1\.Any other pulmonary diagnosis like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Asthma, Cystic fibrosis, Tuberculosis, Lung cancer etc.
- •2\.Known case of Diabetes Mellitus
- •3\.Patients with poorly controlled Hypertension ( \>\=160 / 100 mmHg).
- •4\.Patients on prolonged ( \> 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
- •5\.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho\-Neuro\-Endocrinal disorders etc).
- •6\.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
- •7\.Symptomatic patients with clinical evidence of Heart failure.
- •8\.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) \> 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine \>1\.2mg/dL).
- •9\.Smokers/alcoholics and/or drug abusers.
- •10\.Patients who have completed participation in any other clinical trial during the past six (06\) months.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical Investigation of Efficacy and Safety in Second-line Bevacizumab treatment combined with FOLFIRI or FOLFOX for metastatic colorectal cancercolorectal cancerJPRN-UMIN000001547Tsukuba Cancer Clinical Trial Group400
Completed
Not Applicable
Exploratory study for the efficacy and safety of Sansoninto on behavioral and psychological symptoms of dementia (BPSD) in patients with Dementia.: Multicenter trialDementia patients with BPSDJPRN-UMIN000021562Kanazawa University20
Not yet recruiting
Not Applicable
Effect of products on pimplesCTRI/2024/08/072208KOP research centre private limited
Recruiting
Not Applicable
Evaluation of clinical efficacy and safety of sentinel lymph node biopsy using magnetic nanoparticle and magnetic probeBreast cancerJPRN-UMIN000031240Japan Agency for Medical Research and Development180
Completed
Phase 4
Evaluation of therapeutic efficacy and safety of artesunate-amodiaquine, artemether-lumefantrine and dihydroartemisinine-piperaquine for the treatment of uncomplicated Plasmodium falciparum in Democratic Republic of CongoMalariaInfection - Studies of infection and infectious agentsACTRN12616001423404Ministry of Health534